English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Review question / Objective: The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of escitalopram and agomelatine in the major depressive disorder. Condition being studied: Major depressive disorder (MDD), is one of the most common, costly, and disabling mental health conditions worldwide, with an estimated 246 million sufferers globally in 2020.At present, there is a great demand for effective antidepressant treatment in medicine.  Information sources: We will search, with no time restrictions, the following databases for relevant English language literature: PubMed, the Cochrane Central Register of Controlled Trials and Web of Science. The search string will be built as follows: (escitalopram) AND (agomelatine) AND (major depressed disorder).

Efficacy and safety of escitalopram and agomelatine in the treatment of major depressive disorder-A meta-analysis